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Background: Current evidence suggests that blood eosinophil levels (Eos) are associated with chronic
obstructive pulmonary disease (COPD) treatment response and natural history. This analysis investigated
the relationship between Eos levels and clinical characteristics in a representative cohort of US subjects
with spirometry-deﬁned COPD.
Methods: Cross-sectional data from the National Health And Nutrition Examination Survey (NHANES
2007e2010) of subjects 40 years with spirometry-deﬁned COPD and Eos data (n ¼ 948) were analyzed.
Differences in clinical characteristics by Eos level (2%, >2%) were compared using chi-square tests.
Characteristics associated with Eos >2% were identiﬁed using multivariate logistic regression modeling.
Characteristics associated with Eos >2% among subjects with normal lung function, plus other cut-points
among the COPD population, were evaluated post hoc.
Findings: Most participants had Eos >2%; 70.7% with spirometry-deﬁned COPD and 65.5% with normal
lung function. Older age, male gender, and severe current asthma were signiﬁcantly associated with Eos
>2% in COPD subjects. The Eos 2% COPD group had higher reported rates of previous heart attack and
anemia. Among participants with normal lung function, Eos >2% was associated with being male, being
overweight/obese, older age, hay fever, and congestive heart failure.
Interpretation: In this large US-based cohort, Eos >2% was prevalent in participants with COPD and
normal lung function. Among participants with COPD, Eos >2% was associated with speciﬁc character-
istics including lower rates of some co-morbidities; however, the clinical implications and relationships
between Eos levels, COPD mechanisms, and risk of outcomes require further evaluation.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As chronic lower respiratory conditions, including chronic
obstructive pulmonary disease (COPD), are the third leading cause of
death in the United States [1], signiﬁcant research has been con-
ducted to better understand the heterogeneity of COPD and maxi-
mize patient outcomes. Guidelines, including the Global initiative
for chronic Obstructive Lung Disease (GOLD) consensus report, now
identify subgroups of patients and speciﬁc disease phenotypes
when recommending optimal treatment regimens [2,3].).
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Ltd. This is an open access article uTo better understand COPD heterogeneity and predict out-
comes, biomarkers continue to be an important area of research
[4e6]. Although sputum and tissue eosinophils have been estab-
lished as a measure of inﬂammation in asthma phenotypes [7],
increasing evidence suggests that blood eosinophil levels (Eos) may
be related to disease phenotypes and treatment response in COPD
[3,8e11]. This analysis examined the prevalence of Eos levels >2%
and identiﬁed characteristics associated with Eos >2% among
subjects with COPD in a US population-based cohort.
2. Methods
2.1. Study design
Data from the National Health And Nutrition Examinationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2007e2008 and 2009e2010 surveys, were used in this analysis. As
the data collection methodology used in the 2007e2008 and
2009e2010 surveys was the same for the variables included in this
analysis, the data could be combined. NHANES is a cross-sectional,
clinical patient survey program of the National Center for Health
Statistics of the Centers for Disease Control and Prevention, which
has been ongoing for more than 50 years. Since 1999, more regu-
larly recurring surveys have been conducted to characterize pop-
ulation health in the United States [12]. The NHANES survey has
been used extensively to study the US COPD population [13e16],
and employs a stratiﬁed multistage clustered probability sampling
strategy to ensure generalizability to the non-institutionalized US
population. Questionnaires are completed in participants' house-
holds, with laboratory measures and physical examinations,
including pulmonary function testing, completed in specially
equipped mobile examination centers.
2.1.1. Cohort identiﬁcation
Participants who were 6e79 years of age with no disqualifying
medical conditions were eligible for spirometry and administered
lung function testing in accordance with American Thoracic Society
standards [17]. For this analysis, pre-bronchodilator values meeting
acceptable quality standards were used to identify subjects with
COPD, who were categorized based on the 2006 GOLD COPD
criteria: a forced expiratory volume in the ﬁrst second (FEV1)/
forced vital capacity (FVC) ratio <0.7 and a FEV1 80% of predicted
(stage I), 50e79% of predicted (stage II), 30e49% of predicted (stage
III), or <30% of predicted (stage IV) [18]. Predicted values for
spirometry accounted for age, sex, weight, height, and race/
ethnicity [19]. Post-bronchodilator values were obtained on aFig. 1. CONSORT diagram. BMI ¼ body mass index. COPD ¼ chronic obstructive pulmonar
second. FVC ¼ forced vital capacity. NHANES¼National Health And Nutrition Examinationlimited basis but were not used in this analysis. Subjects with
questionable or invalid results were excluded [20]. Participants in
the analysis were required to be 40 years old and have a GOLD
spirometry-deﬁned classiﬁcation of stage I, II, III, or IV, with stage III
and IV considered as severe COPD. Participants were also required
to have non-missing Eos counts and Eos percentages as a function
of the total white blood cell counts.
As a post-hoc analysis, participants with ‘normal’ lung function
were utilized as a comparison group. ‘Normal’ lung function was
deﬁned as having no evidence of respiratory disease: adults
40e79 years with no evidence of restriction (FEV1/FVC ratio 0.7
with FVC <80% of predicted) [13] and no self-reported current
asthma, chronic bronchitis, emphysema, and/or bringing up
phlegm on most days in the prior 3-month period. Normal lung
function subjects were also required to have Eos measurements.
As a post-hoc sensitivity analysis, the factors associated with
higher (Eos >4%) and lower (Eos1%) blood eosinophils, and based
on a cut-point of 200 cells per ml, were also examined.
2.1.2. Clinical characteristics
Subject demographics, smoking status, Eos levels, and co-
morbidities, along with any self-reported diagnoses of chronic bron-
chitis, emphysema, and bringing up phlegmmost days in the prior 3-
month period, were characterized and included in the modeling.
Subject demographics and smoking were classiﬁed as follows:
age (40e49, 50e59, 60e69, and 70e79 years); race/ethnicity
(Caucasian, non-Hispanic black, or Mexican-American); body mass
index (BMI; missing, <18.5 [underweight], 18.5e24.9 [normal],
25e29.9 [overweight], and30 [obese]); smoking (current, former,
or never, based on responses to questions about smoking history/
frequency; former or current smokers had to have smoked 100y disease. Eos ¼ blood eosinophil levels. FEV1 ¼ forced expiratory volume in the ﬁrst
Survey.
Table 1
Characteristics of subjects with spirometry-deﬁned COPD and normal lung function.
Spirometry-deﬁned COPD Normal lung function
n Weighted % n Weighted %
Overall 948 100.0 3123 100.0
Age group (years)
40e49 146 20.1 1090 40.9
50e59 220 32.3 862 32.1
60e69 310 28.9 752 18.1
70e79 272 18.6 419 8.9
Male 610 59.7 1490 47.5
Any current asthma (non-severe or severe) 111 11.7 e e
Current non-severe asthma 74 8.2 e e
Current severe asthma 37 3.5 e e
Any history of asthma 167 18.5 139 4.5
Phlegm (most days in the prior 3 months) 150 14.3 e e
Smoking
Current 323 32.3 465 12.9
Former 373 38.4 883 28.5
Never 252 29.3 1775 58.6
Smoking (pack-years)
<10 438 48.9 2442 77.5
10 510 51.1 681 22.5
GOLD stage
GOLD stage I 513 58.0 e e
GOLD stage II 374 36.6 e e
GOLD stage III 60 5.4 e e
GOLD stage IV 1 0.0 e e
Blood Eos (cells/mL)
<200 344 35.3 1375 45.1
200e<300 295 32.3 992 31.0
300e<400 172 18.3 424 14.2
400 137 14.1 332 9.7
Blood Eos (%)
2% 270 29.3 1039 34.5
>2e3% 271 27.8 953 29.9
>3e4% 162 16.7 496 15.3
>4e5% 102 11.5 275 9.2
>5% 143 14.7 360 11.1
COPD ¼ chronic obstructive pulmonary disease. Eos ¼ blood eosinophil levels. GOLD ¼ Global initiative for chronic Obstructive Lung Disease.
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Subject co-morbidities were determined based on self-reported
diagnosis of medical conditions and included asthma, diabetes,
treated hypertension, congestive heart failure (CHF), coronary heart
disease, heart attack, anemia, liver abnormalities, arthritis, high
cholesterol, hay fever, and food allergy. Current asthma status was
categorized as no current asthma, current non-severe asthma, or
current severe asthma. Current non-severe and severe asthmawere
based on NHANES deﬁnitions. To be classed as having current
asthma, subjects were required to answer two questions in the
afﬁrmative: ‘Has a doctor ever told you that you have asthma?’ and
‘Do you still have asthma?’. Current severe asthma included sub-
jects with current asthma who additionally fulﬁlled 2 of the
following criteria in the past 12 months: an asthma episode or
attack, a visit to emergency department or urgent care because of
asthma, 6 attacks of wheezing or whistling, 2 visits to the
doctor's ofﬁce or the hospital emergency department for 1 of the
attacks of wheezing or whistling, and/or 8 days of work/school
missed due to wheezing or whistling.
2.2. Analysis
Data analysis was completed using SAS (Statistical Analysis
System, version 9.2; SAS Institute, Cary, NC, USA). The NHANES
2007e2010 sampling frame information (primary sampling units
and strata) and the mobile examination center/home examination
ﬁnal weights were used in all of the analyses.
Participant characteristics were summarized using frequency
and logistic regression procedures that adjusted for the complexNHANES sampling design and survey weights. Differences in clin-
ical characteristics by Eos level (>2% vs 2%) were tabulated using
the chi-square test. To adjust for multiple subject characteristics,
logistic regressionwas used with the outcome as the presence (yes/
no) of Eos >2% as the primary outcome. Explanatory variables
included COPD lung function (as per GOLD 2006 guidelines) [18],
chronic bronchitis, emphysema, bringing up phlegm most days in
the prior 3-month period, demographics, smoking status, current
asthma status, and co-morbidities. Due to the number of clinical
characteristics relative to the total sample size and prevalence of
Eos >2%, a stepwise model selection strategy was employed, such
that explanatory variables entered and remained in themodel if the
p-values achieved the 0.10 level of signiﬁcance. If one level within a
categorical variable was signiﬁcant (for age or current asthma sta-
tus), all levels within the categories were retained. The modeling
strategy was repeated excluding participants with any current
asthma and current severe asthma and for additional post-hoc
blood eosinophil thresholds in participants with COPD (Eos >4%,
Eos1%, Eos >200 cells/ml of blood). Goodness-of-ﬁt statistics were
used to evaluate the logistic regressionmodels. Weighted summary
statistics are presented that are reﬂective of the distribution of the
US population.
Participant characteristics by Eos levels and predictors of Eos
>2% in subjects with normal lung functionwere described as part of
the post-hoc analysis. The analytic strategy described for partici-
pants with COPD was also employed for participants with normal
lung function. Plots of Eos data were also produced to compare the
distributions between participants with COPD and normal lung
function.
Fig. 2. Distribution of % blood eosinophils among participants with (A) spirometry-deﬁned COPD and (B) normal lung function. Distribution of Eos % for participants with COPD and
normal lung function; distributions of unweighted sample. Normal lung function (n ¼ 3123): median 2.5, mean 2.94, minimum 0.4, 25th percentile 1.7, 75th percentile 3.6,
maximum 24.0. COPD (n ¼ 948): median 2.6, mean 3.27, minimum 0.4, 25th percentile 1.8, 75th percentile 4.0, maximum 21.3. COPD ¼ chronic obstructive pulmonary disease.
Eos ¼ blood eosinophil levels.
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3.1. Study population
A total of 17,515 subjects in the NHANES 2007e2010 cohorts
were eligible for spirometry measurements; of these, 8675 were
aged 20e79 and had valid spirometry measurements and data on
age, gender, and BMI (necessary for calculation of predicted lung
function). After applying all entry criteria, 948 participants with
spirometry-deﬁned COPD (FEV1/FVC <0.7) and 3123 participants
with normal lung function were included in the analysis (Fig. 1).
Overall, 70.7% of participants with COPD and 65.5% of thosewith
normal lung function had Eos >2% (Table 1), with similar distri-
butions of Eos percentages (Fig. 2) and count. In participants with
COPD, the distribution of Eos levels ranged from 0.4 to 21.3%, with a
mean of 3.3% and median of 2.6%. The distribution of Eos among
COPD patients by smoking status (current/former vs never) was
also similar (see Supplementary Fig. 1). Eos levels among partici-
pants with normal lung function ranged from 0.4 to 24.0%, with a
mean of 2.9% and median of 2.4%. Participants with COPD without
co-morbid current asthma (non-severe or severe) had a similar
proportion of Eos >2% (69.6% [data not shown]).COPD subjects were mostly classiﬁed as having milder disease
(58.0% were classed as GOLD stage I, 36.6% as stage II, and 5.4% as
stage III or IV). The majority of COPD subjects were male (59.7%),
aged 50e69 (61.2%), and current/former smokers (70.7%), with
11.7% reporting any concomitant current asthma. As expected,
participants with normal lung function and no current respiratory
disease tended to be younger (40.9% were 40e49 years) and never
smokers (58.6%).
Participants with COPD and Eos >2% were signiﬁcantly (chi-
square test p < 0.05 comparing >2% vs2%) more likely to be older;
male; have any current asthma, current severe asthma, or severe
COPD (GOLD stage III/IV); and were less likely to have been diag-
nosed with anemia (Table 2). Among the population with normal
lung function and using the same cut-point, being male, over-
weight or obese, prescribed hypertension treatment, and diagnosed
with coronary heart disease, hay fever, or congestive heart failure,
were each associated with Eos >2%, while smoking status (former
vs never smokers) was marginally signiﬁcant (Table 2).
Logistic regression modeling was used to identify factors inde-
pendently associated with Eos >2%. Among the COPD population,
older age, being male, and having current severe asthma versus no
current asthma were factors associated with Eos >2%. In contrast,
Table 2
Characteristics and co-morbidities by blood eosinophil level for subjects with spirometry-deﬁned COPD and normal lung function.
Spirometry-deﬁned COPD Normal lung function
Low Eos (2%) High Eos (>2%) Low Eos (2%) High Eos (>2%)
N Weighted % N Weighted % N Weighted % N Weighted %
Overall 314 100.0 634 100.0 1204 100.0 1919 100.0
Age group (years) *
40e49 61 26.6 85 16.8 451 43.3 639 39.3
50e59 81 33.8 139 31.6 341 31.6 521 32.5
60e69 89 23.0 221 32.0 269 17.2 483 18.6
70e79 83 16.6 189 19.7 143 7.9 276 9.6
Male 185 52.9 425 63.3* 521 42.1 969 51.0*
Race
Caucasians 211 87.3 431 88.8 583 78.2 910 77.2
African American 57 8.3 103 6.6 195 8.8 370 10.2
Mexican American 46 4.4 100 4.6 426 12.9 639 12.6
BMI *
Underweight 11 3.1 12 1.7 7 0.7 10 0.8
Normal 101 36.6 195 29.9 268 26.1 330 19.3
Overweight 116 35.0 238 41.5 459 36.3 753 39.5
Obese 86 25.3 189 27.0 470 37.0 826 40.4
Smoking y
Current 122 36.7 201 30.1 186 13.1 279 12.9
Former 112 37.5 261 38.8 318 25.5 565 30.4
Never 80 25.8 172 31.1 700 61.4 1075 56.7
Smoking (pack-years)
<10 145 48.9 293 48.9 958 78.8 1484 76.7
10 169 51.1 341 51.1 246 21.2 435 23.3
Any current asthma (non-severe or severe) 25 7.7 86 13.8* e e e e
Current non-severe asthma 18 6.4 56 9.1
Current severe asthma 7 1.3 30 4.6y e e e e
Any history of asthma 43 13.8 124 20.8y 51 4.0 88 4.9
Chronic bronchitis 18 4.5 39 5.3 e e e e
Emphysema 21 4.4 41 6.5 e e e e
Phlegm (most days in the prior 3 months) 49 13.6 101 14.7 e e e e
GOLD stage
GOLD stage I 172 59.4 341 57.3 e e e e
GOLD stage II 127 37.5 247 36.2 e e e e
GOLD stage III 15 3.1 45 6.5 e e e e
GOLD stage IV e e 1 0.0 e e e e
Severe COPD *
Non-severe (stage I/II) 299 96.9 588 93.4 e e e e
Severe (stage III/IV) 15 3.1 46 6.6 e e e e
Diabetes 48 10.1 81 8.7 141 7.7 246 9.2
Treated hypertension 121 32.0 278 38.3 396 27.2 684 31.9*
Congestive heart failure 19 4.2 22 2.6 10 0.5 38 1.4*
Coronary heart disease 24 5.6 50 6.2 25 1.7 72 3.1*
Heart attack 30 7.3 54 5.3 29 2.1 61 2.5
Anemia 19 6.3 19 2.7* 32 2.2 65 3.1
Liver 12 2.6 23 2.4 46 3.1 68 3.8
Arthritis 128 38.7 266 38.1 340 27.8 598 29.2
High cholesterol 97 29.1 226 31.1 320 23.3 513 25.1
Hay fever 46 17.3 133 24.8 153 14.5 301 20.8*
Food allergy 33 10.6 49 7.3 100 8.5 172 9.6
*p< 0.05; yp< 0.1. BMI¼ bodymass index. COPD¼ chronic obstructive pulmonary disease. Eos¼ blood eosinophil levels. GOLD¼Global initiative for chronic Obstructive Lung
Disease.
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attack or anemia than those with Eos >2% (Fig. 3A).
When excluding COPD subjects with any current asthma or with
current severe asthma, factors associated with Eos >2% were
generally similar to the primary COPD analysis (see Supplementary
Fig. 2). However, when excluding subjects with any current asthma,
subjects with Eos 2% were more likely to have a history of CHF or
diabetes, rather than heart attack and anemia. Among participants
with normal lung function, Eos >2% was independently associated
with being male, being overweight or obese, older age, and prior
diagnosis of CHF and hay fever (Fig. 3B).
A post-hoc analysis evaluated the sensitivity of the results to the
chosen Eos cut-point, as well as to Eos cell counts, in patients with
COPD. In patients with COPD, the association with current severe
asthmawas also observedwith higher Eos values (Eos>4%; Fig. 4A).Eos 1% was associated with CHF and anemia, consistent with
participants with Eos <2%. Eos 1% was also associated with non-
severe asthma (vs no asthma) and food allergy (Fig. 4B). Utilizing
a cut-point of 200 cells per ml of blood found similar results to the
primary endpoint. Eos >200 cells per ml was associated with severe
asthma (vs no asthma) and a lower risk of anemia (see
Supplementary Fig. 3).
4. Discussion
In this nationally representative dataset of the US population,
Eos >2%was prevalent in subjects with COPD (70.7% of participants,
estimated 12.8 million population), which is consistent with ob-
servations from clinical trial populations [10], and associated with
increased age, male gender, current asthma severity, and a lower
Fig. 3. Characteristics associated with blood eosinophils >2%. (A) COPD patients with spirometry-based COPD deﬁnition GOLD IeIV (FEV1/FVC <0.7); (B) subjects with normal lung
function with FEV1/FVC ratio 0.7, and FVC % predicted 80%, and no self-reported current asthma, chronic bronchitis, emphysema, and/or bringing up phlegm most days in the
prior 3-month period. Multivariate regression stepwise model (p entry 0.1 e p retain 0.1 in the model) of factors associated with blood Eos levels >2% vs 2% among NHANES
2007e2010 subjects, aged 40 years, with blood Eos data on both Eos % and Eos count. COPD ¼ chronic obstructive pulmonary disease. CHF ¼ congestive heart failure. Eos ¼ blood
eosinophil levels. FEV1 ¼ forced expiratory volume in the ﬁrst second. FVC ¼ forced vital capacity. GOLD ¼ Global initiative for chronic Obstructive Lung Disease.
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similar in sensitivity analyses excluding subjects with current
asthma. In contrast to what might be hypothesized, the distribution
of Eos levels was similar between subjects with COPD and those
with normal lung function, as well as by smoking status among
subjects with COPD. Among participants with normal lung func-
tion, Eos >2% was associated with male gender and older age (as in
the COPD subgroup); however, being overweight or obese, and
having been diagnosedwith CHF or hay feverwere the other factors
more likely to be seen in those with Eos >2%.There is some suggestion that subjects with lower Eos (<2%)
have more severe COPD and/or co-morbidities, but the clinical
importance is not fully understood. In a longitudinal analysis of the
ECLIPSE cohort (Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints; NCT00292552), COPD patients
with persistent eosinophilia (2%) had signiﬁcantly higher FEV1%
predicted and fat-free mass, and lower St George's Respiratory
Questionnaire (SGRQ) and Modiﬁed Medical Research Council
Dyspnea scores [21]. However, the differences were not considered
clinically important. A greater progression of emphysema and
Fig. 4. Characteristics associated with blood eosinophils (A) >4% among COPD patients with spirometry-based COPD deﬁnition GOLD IeIV (FEV1/FVC <0.7); (B) 1% among COPD
patients with spirometry-based COPD deﬁnition GOLD IeIV (FEV1/FVC <0.7). Multivariate regression stepwise model (p entry 0.1 e p retain 0.1 in the model) of factors associated
with blood Eos levels >4% vs 4% and 1% vs >4% among NHANES 2007e2010 subjects, aged 40 years, with blood Eos data on both Eos % and Eos count. COPD ¼ chronic
obstructive pulmonary disease. CHF ¼ congestive heart failure. Eos ¼ blood eosinophil levels. FEV1 ¼ forced expiratory volume in the ﬁrst second. FVC ¼ forced vital capacity.
GOLD ¼ Global initiative for chronic Obstructive Lung Disease.
R.L. DiSantostefano et al. / Respiratory Medicine 112 (2016) 88e9694worsening in SGRQ score was observed in patients with persistent
lower Eos counts. In the SPIROMICS study, subjects with lower
baseline Eos (<1%) had more severe COPD, evidenced by a greater
degree of obstruction, shorter 6-minute walk distances, and higher
numbers of exacerbations, and were more commonly GOLD stage
III or IV [22]. Associations withmore severe COPDwere not noted in
this study, although the results suggest a greater prevalence of co-
morbidities among subjects with Eos 2% including prior heart
attack and anemia (also diabetes and CHF when excluding those
with any current asthma). Associations with other ‘low eosinophil’
cut-points in our analysis (e.g., Eos 1%) included an increased risk
of anemia and CHF.
The increase in co-morbidities in the Eos 2% participants with
COPD may be due to underlying genetic differences in response to
inhalation of noxious agents, particularly cigarette smoke [23].Bacterial infections are also known to cause eosinopenia and the
Eos 2% group may have greater bacterial colonization [24]. This
hypothesis is somewhat supported by the higher incidence of
anemia in the Eos 2% group and Eos 1%, as anemia is associated
with chronic inﬂammatory conditions, including infection [25,26].
Interestingly, the comparison between subjects with COPD and
those with normal lung function revealed potentially conﬂicting
results for the association between Eos and CHF. Among COPD
subjects without any current asthma, Eos >2% was associated with
a lower risk of CHF, while in subjects with normal lung function, Eos
>2% was associated with a greater risk of CHF diagnosis. The
explanation for this is unclear and requires further research. The
association between Eos 1% and non-severe asthma and food al-
lergy, which are characterized by eosinophilic response, are also
unclear, but may be spurious and related to the small sample size of
R.L. DiSantostefano et al. / Respiratory Medicine 112 (2016) 88e96 95patients with both Eos 1% and either of these conditions.
Eos measurements as a percentage of white blood cells versus a
count in cells/mL are correlated [10]; therefore, an evaluation of
patient characteristics associated with Eos >200 cells/mL found
similar associations with severe asthma and anemia to those found
using the >2% cut-point in the populations of interest. Analyses
utilizing a cut-point based on cell counts were limited, however,
due to the structure of the NHANES data. Data on Eos counts in the
NHANES dataset are presented as 1000 cells/ml and rounded to one
decimal place, with values ranging from 0.1 to 1.6, a median of 0.2,
and 25th/75th percentiles of 0.1 and 0.3, respectively, among the
COPD subjects in this analysis. These values only allow for catego-
rization of patients by Eos count to the nearest 100 cells/ml, and do
not allow for more granular cut-points, such as 150 cells/ml. Due to
the distribution of Eos counts and rounding manipulation inherent
to the NHANES dataset, analyses based on other cut-points were
not feasible.
This analysis does have certain limitations. Lung function
measurement in NHANES is limited to those <80 years of age. In
addition, participants were ineligible to receive spirometry if they
had health conditions that would make them uncomfortable or
potentially put their health at risk (e.g., a physical problem with
forceful expiration, taking supplemental oxygen, recent surgery
of the eye, chest or abdomen, recent heart attack, or current chest
pain). These exclusions may have resulted in under-
representation of subjects with more severe COPD from this
sample population. Further, lung function was measured at a
single time point using a ﬁxed cut-off, and this analysis utilized
pre-bronchodilator values; thus, there may have been some
misclassiﬁcation of COPD according to current guidelines [2].
Post-bronchodilator values were not used due to attrition
(n ¼ 316 with post-bronchodilator conﬁrmed COPD) and to
ensure adequate sample size. Participants excluded from the
post-bronchodilator measurements included those who declined,
plus those with speciﬁed cardiovascular conditions, select medi-
cations, and recent bronchodilator use. Despite these limitations,
COPD classiﬁcation based on spirometry may offer advantages
over self-reported diagnosis alone due to challenges in dis-
tinguishing between asthma and COPD in a clinical setting
without lung function tests, particularly in patients over 40 years
[27]. Eos cell count may be a more meaningful measurement to
identify patients in a clinical setting, but, as stated above, the
structure of the NHANES dataset and distribution of Eos cell
counts did not allow for further analysis by other Eos cut-points.
Although a more robust analysis of Eos cell count cut-points was
not possible, there is a concordance between Eos % and Eos
counts [10]. Finally, as the assessments were cross-sectional, it is
not possible to determine the direction of the relationship be-
tween Eos levels and co-morbidities or longitudinal COPD
outcomes.
5. Conclusion
Mounting evidence suggests that Eos may be a useful biomarker
in COPD. In our nationally representative US population, increases
in Eos levels are associated with increased age, male gender, and
current severe asthma. This may be clinically important as other
studies have found that Eos levels may affect response to oral and
inhaled corticosteroids [8,28]. Lower Eos values may also be clini-
cally important, as COPD patients with lower Eos (2%) exhibit an
increased risk of co-morbidities (i.e., anemia and CHF) and may not
be as responsive to corticosteroids, warranting closer clinical
monitoring. While these associations are interesting, the clinical
signiﬁcance and relationship between COPD disease mechanisms
and outcomes requires further evaluation.Contributors
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